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Introduction
In Germany, the Standing Committee on Vaccination 
(STIKO) develops and endorses national vaccination recommen-
dations. The current routine childhood immunization schedule 
comprises 12 vaccinations. According to this schedule, primary 
childhood immunizations should be completed by 24 mo of age 
or earlier.1,2 This includes four doses of diphtheria (DIP), tetanus 
(TET), pertussis (PER), polio (IPV), Haemophilus influenzae 
type b (HIB), hepatitis B (HEPB), and pneumococcal conjugate 
vaccine (PCV), as well as two doses of measles (MCV), mumps 
(MUM), rubella (RUB) vaccines preferably administered as a 
measles-mumps-rubella (MMR) combination vaccine, two doses 
of a varicella vaccine (VAR), and a single dose of meningococcal 
C vaccine (MENC). In cases of missing vaccinations, individual 
catch-up is recommended for children beyond the second year of 
life with the exception of PCV. Whereas most vaccinations are part 
of the schedule for decades (including routine childhood HEPB 
vaccination, which was introduced in the mid-1990s), PCV and 
MENC were adopted in 2006 and single-dose VAR in 2004. 3 A 
second dose of VAR is universally recommended since 2009.
Valid data on vaccination coverage (VC) and VC trends are 
needed to assess the performance of national immunization pro-
grams. This permits program modification and the adaption of 
measures to increase acceptance and vaccine uptake. VC data are 
also helpful for the estimation of vaccine effectiveness and inter-
pretation of adverse events signals. Furthermore, country-level 
VC data are internationally collected and compared in order to 
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In Germany, the national routine childhood immunization schedule comprises 12 vaccinations. Primary immuniza-
tions should be completed by 24 mo of age. however, nationwide monitoring of vaccination coverage (Vc) is performed 
only at school entry. We utilized health insurance claims data covering ~85% of the total population with the objectives 
to (1) assess Vc of all recommended childhood vaccinations in birth-cohorts 2004–2009, (2) analyze cross-sectional (at 
24 and 36 mo) and longitudinal trends, and (3) validate the method internally and externally. counting vaccine doses in 
a retrospective cohort fashion, we assembled individual vaccination histories and summarized Vc to nationwide figures. 
For most long-established vaccinations, Vc at 24 mo was at moderate levels (~73–80%) and increased slightly across 
birth-cohorts. One dose measles Vc was high (94%), but low (69%) for the second dose. Vc with a full course of recently 
introduced varicella, pneumococcal, and meningococcal c vaccines increased across birth-cohorts from below 10% 
above 60%, 70%, and 80%, respectively. at 36 mo, Vc had increased further by up to 15 percentage points depending on 
vaccination. Longitudinal analysis suggested a continued Vc increase until school entry. Validation of Vc figures with pri-
mary data showed an overall good agreement. In conclusion, analysis of health insurance claims data allows for the esti-
mation of Vc among children in Germany considering completeness and timeliness of vaccination series. This approach 
provides valid nationwide Vc figures for all currently recommended pediatric vaccinations and fills the information gap 
between early infancy and late assessment at school entry.
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assess the current state of efforts to control or eliminate vaccine-
preventable diseases.4
In Germany, immunization is voluntary. All administered 
vaccines are documented on individual vaccination cards. 
However, there is no central register t hat allows for VC analy-
ses at national level. Various sources of VC data have previously 
been identified.5,6 These include primary data from surveys 
such as kindergarten entrance examinations (KEE), performed 
merely in a few federal states. Annual school entrance examina-
tions (SEE) are the sole primary VC data source that is continu-
ously and nationwide exploited. At the time of SEE, children 
are four to seven years of age. As a consequence, at country-
level there is neither VC data on young children (e.g., at 24 
mo of age) available nor data on recently introduced pediatric 
vaccinations.
The usefulness of health insurance claims data for the 
estimation of VC has previously been demonstrated.7-10 In an 
approach to complement existing nationwide VC monitoring 
through SEE, we analyzed data of health insurance refund 
claims from Associations of Statutory Health Insurance 
Physicians (ASHIPs) with the objectives (1) to estimate VC of 
all recommended childhood vaccinations at national level, and 
(2) to investigate VC trends by birth-cohort in cross-sections 
at 24 and 36 mo and in a longitudinal approach up to school-
age. A further objective of this research project was (3) to vali-
date the method internally and with primary VC monitoring 
data from KEE and SEE to provide evidence for or against the 
implementation of ASHIP data analysis for routine assessment 




Between 2004 and 2009, an overall 4 096 643 live births were 
registered in Germany of which 69.1% were born in the investi-
gated years of birth and ASHIP regions. Among those, 1 592 400 
(56.3%) fulfilled the inclusion criteria for the 24 mo follow-up 
(range over regions and year-of-birth: 42.6–68.5%). Sample sizes 
of cohorts with 36 mo follow-up were comparable. Sample sizes 
for longitudinal analysis in two ASHIP regions were n = 47 533 in 
Saxony-Anhalt and n = 60 078 in Schleswig-Holstein, representing 
45.9% and 43.7% of live births in these regions.
Trend analysis of birth cohorts 2004–2009
VC at national level for birth cohorts 2004–2009 is shown 
in Figure 1. At 24 mo, VC for 4th DIP, TET, PER, IPV, and 
HIB were 80% on average and slightly increased from birth 
cohorts 2004 to 2006 but not thereafter. 4th HEPB dose VC was 
approximately 73% and increased between birth cohorts 2004 
and 2007 but not thereafter. VC for 1st MMR was in all birth 
cohorts above 92%, and VC for 2nd MMR increased from 59% 
to 69%. Across all birth cohorts, VC of the newly introduced 
vaccines 4th PCV, MENC, and 2nd VAR increased from low 
levels (4%, 8%, and 1%) to 72%, 81%, and 64%, respectively.
By the age of 36 mo, VC for birth cohorts 2004–2008 
increased further on average by 15 percentage points (pp) (2nd 
MMR), 9 pp (2nd VAR), 13 pp (MENC), 7 pp (4th DIP, TET, 
PER, IPV, HIB, HEPB), and 3 pp (4th PCV).
Figure 1. Vaccination coverage in Germany for birth cohorts 2004 up to 2009, at the age of 24 mo and 36 mo based on health insurance claims data 
analysis. Upper and lower bounds of confidence intervals are omitted and were ≤0.2 percentage points above or below point estimates. DIP, diphtheria 
vaccine; TeT, tetanus vaccine; PeR, pertussis vaccine; IPV, polio vaccine; hIB, Haemophilus influenzae type b vaccine; hePB, hepatitis B vaccine; PcV, pneu-
mococcal conjugate vaccine; MeNc, meningococcal c vaccine; McV, measles vaccine; MUM, mumps vaccine; RUB, rubella vaccine; VaR, varicella vaccine.
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VC at 24 and 36 mo by ASHIP and birth-cohort is provided 
as supplemental material.
Longitudinal analysis of birth cohorts 2004–2009
The progression of VC within and across birth cohorts as a 
function of age is exemplified in Figure 2 for selected vaccina-
tions in the two regions of ASHIPs Saxony-Anhalt and Schleswig-
Holstein. In both ASHIP regions, a strong increase starting at 
the recommended age was evident proceeding toward the end of 
the second year of life. However, the increase continued beyond 
24 mo and featured distinct periods of increase that coincided 
with the provision of well-child check-ups in Germany. Among 
the well-child check-ups at two years of age and later, the period 
of the routine check-up performed at 20 to 27 mo featured the 
strongest VC alterations. Overall, we observed an increase of VC 
across birth cohorts; among the ones displayed, VAR vaccina-
tions involved the strongest changes.
Validation of VC estimation
Comparison of VC from ASHIP data with kindergarten entrance 
health examinations
We calculated the median differences of corresponding VC 
point estimates from ASHIP data and KEE Schleswig-Holstein 
for each vaccination as depicted in Figure 3. On average the 
median difference between ASHIP and KEE point estimates 
was 0.7 pp (range of median differences -6.0 pp to 8.1 pp) 
(Fig. 3).
Figure 2. cumulative vaccination coverage among birth cohorts 2004 to 2009 in relation to age. Depicted are figures for the associations of statutory 
health Insurance Physicians (ashIP) regions saxony-anhalt and schleswig-holstein based on health insurance claims data analysis. solid lines: 1st or 4th 
dose, respectively; dashed lines: 2nd dose. TeT, tetanus vaccine; McV, measles vaccine; VaR, varicella vaccine.
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Comparison of VC from ASHIP data with school entrance health 
examinations
VC from ASHIP data analysis and from SEE Saxony-Anhalt 
is shown in Figure 4. The ASHIP-estimate for 2nd MMR fit-
ted well within the range of SEE average case and worst case 
scenario. VC of DIP, TET, PER, and MENC from ASHIP data 
analysis were closer to the SEE worst case and 1st MMR was 
closer to the SEE average case (overlapping confidence intervals 
[CIs]). VC of IPV, HIB, HEPB, and PCV were 2.5 pp, 2.3 pp, 
6.1 pp, and 8.0 pp below the SEE worst case and VC of 1st and 
2nd VAR was 2.7 pp and 5.7 pp above the SEE average case 
scenario (no overlapping CIs).
Re-capture of patients by screening for specific vaccination code 
extensions
In vaccination claims of children who had a history of 
receiving a complete vaccination series of two or four doses, 
5.4% (range 4.3–8.2%) and 7.5% (range 7.1–8.1%) of the final 
doses, respectively, were falsely coded as to indicating a non-
completing dose.
In claims of children with a history of receiving non-com-
pleting 1st or 3rd dose, 0.8% (range 0.2–1.1%) and 5.1% (range 
2.6–11.9%) of the doses, respectively, were falsely labeled as 
completing.
Discussion
In Germany, STIKO recommends to complete primary child-
hood immunizations by the end of the second year of life. In 
the absence of a system for continuous and nationwide VC data 
collection and assessment for this age-group, we utilized health 
insurance claims data from ASHIPs to estimate VC, analyzed 
trends in birth cohorts 2004–2009 in a cross-sectional and longi-
tudinal fashion, and validated the method.
For the external validation we compared VC estimated from 
ASHIP data for a number of single month-of-birth cohorts at 
different age with data from KEE in Schleswig-Holstein. We also 
compared VC estimates from ASHIP data analysis with SEE esti-
mates in Saxony-Anhalt. In KEE Schleswig-Holstein, 89.6% of 
data collection forms were turned in by the physicians.11 Reasons 
for non-response are unknown, and assumptions on the vaccina-
tion status of non-responding children are difficult to make. In 
contrast, the assessment of VC among school children requires 
average case and worst case consideration: SEE exclusively rely 
on presented vaccination cards, and it has been shown previously 
that children without vaccination cards can have lower VC12 and 
show higher seronegativity13 as compared with those presenting 
vaccination documents. Despite these limitations, in the absence 
Figure 3. Difference of vaccination coverage (Vc) point estimates from data analysis of the association of statutory health Insurance Physicians (ashIP) 
schleswig-holstein and kindergarten entrance examinations (Kee) in the state of schleswig-holstein. The compared birth cohorts per vaccination 
and definitions of vaccination status are listed in Table 2. Boxes indicate lower and upper quartile, the boxes’ length the interquartile range (IQR), 
horizontal lines indicate medians. Whiskers span all data points within 1.5xIQR of upper or lower quartile, respectively. Dots indicate further data points. 
DIP, diphtheria vaccine; TeT, tetanus vaccine; PeR, pertussis vaccine; IPV, polio vaccine; hIB, Haemophilus influenzae type b vaccine; hePB, hepatitis B 
vaccine; PcV, pneumococcal conjugate vaccine; MeNc, meningococcal c vaccine; McV, measles vaccine; MUM, mumps vaccine; RUB, rubella vaccine; 
VaR, varicella vaccine.
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of an immunization register both KEE and SEE constitute the 
best primary data sources in Germany for the validation of our 
estimates from ASHIP data. Still, with the exemption of the 
newly introduced PCV and VAR vaccines we were able to observe 
an overall good agreement between estimates from ASHIP data 
analysis and both primary sources. With a median VC difference 
to KEE figures of only 0.7 pp on average and with levels usually 
ranging between the SEE average and worst case scenario our 
approach of utilizing ASHIP data has demonstrated to generate 
comparable data.
Although we put a considerable effort on creating cohorts 
from claims data based on date of birth, age, and place to closely 
resemble cohorts from primary sources, variations in the com-
positions of the compared cohorts may have implications on the 
estimated VC. The largest VC differences between ASHIP and 
the primary sources used for validation concern recently intro-
duced vaccinations (VAR and PCV). A reason for these differ-
ences might be that usage of the newly introduced vaccinations is 
more likely to increase quicker over time. As a result, slight cohort 
variations can result in a stronger effect on the corresponding VC 
than on estimates of vaccinations that have been recommended 
for a long time. Some of the sampled children may have received 
vaccinations in regions of different ASHIPs. Those events can-
not be assigned to these patients and could artificially increase 
the number of children with incomplete vaccination schedules. 
According to our inclusion criteria, events merely in the begin-
ning and at the end of follow-up were sufficient for a patient 
to be sampled. The approach only provides a high chance that 
just those patients are selected who have been receiving health 
provisions (i.e., vaccinations) exclusively within their associated 
ASHIP region. We therefore aimed to assess the degree of VC 
underestimation due to these losses to follow-up. Patients were 
recaptured by screening for vaccination claim code extensions 
that indicate doses not completing and completing vaccination 
series. We assumed that the proportion of falsely used code exten-
sions coding non-completing doses in histories of completed vac-
cinations (5.4% and 7.5% for two and four dose schedules) can 
be regarded as a general failure rate in code extension usage. If 
vaccinations were missing in the patient’s history due to intermit-
tent vaccinations in different ASHIP regions, code extensions for 
completing doses would seem prematurely used. However, the 
failure rate in coding non-completing doses (0.8% and 5.1% for 
two and four dose schedules) was even below our assumed gen-
eral failure rate in code extension usage. The degree of intermit-
tent loss to follow-up and resulting VC underestimation due to 
our sampling approach can therefore be regarded as negligible. 
It is important to mention that compliance with recommended 
intervals between administered doses was not part of the defini-
tion of a completed vaccination series in our analysis; the propor-
tion of inconsistently used code extensions for completing doses 
could therefore be an overestimate and some doses might indeed 
be non-completing due to too short intervals between subsequent 
vaccinations.
At 24 mo of age, estimation of VC in birth cohorts 2004–
2009 showed moderate coverage levels with most traditional 
vaccinations at 73–80% and a slightly increasing trend across 
cohorts. With 94%, VC of 1st MMR was relatively high, but 
the 2-dose MMR coverage of 69% at maximum indicates that 
this young age-group is still far below the 2-dose target coverage 
of ≥95% required for the regional elimination of measles and 
rubella by 2015.14 We also found a strong increase of VC across 
birth cohorts for a full course of recently introduced vaccinations 
from well below 10% to moderate levels in the cases of PCV 
(>70%) and MENC (>80%) indicating good acceptance; 
however, VC of 64% for VAR is still relatively low at 24 mo of 
age. Universal vaccination with two doses VAR is the most recent 
Figure  4. Vaccination coverage (Vc) estimated from school entrance examinations (see) in the state of saxony-anhalt and data analysis of the 
association of statutory health Insurance Physicians (ashIP) saxony-anhalt. Only vaccinations documented on vaccination cards were considered in 
the examinations. Vc is related to the number of children presenting a vaccination card (average case scenario) and the total number of children, 
irrespective of the presence of a vaccination card (worst case scenario). Definitions of vaccination status are given in Table 2. Vertical lines represent 95% 
confidence intervals. DIP, diphtheria vaccine; TeT, tetanus vaccine; PeR, pertussis vaccine; IPV, polio vaccine; hIB, Haemophilus influenzae type b vaccine; 
hePB, hepatitis B vaccine; PcV, pneumococcal conjugate vaccine; MeNc, meningococcal c vaccine; McV, measles vaccine; MUM, mumps vaccine; RUB, 
rubella vaccine; VaR, varicella vaccine.
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major change in the national childhood vaccination schedule. 
Low coverage of 2nd VAR might therefore be an expression of 
this recent change and thus based on low utilization rather than 
general weak acceptance.
The comparison of cross-sections of birth cohorts 2004–2008 
at 24 and 36 mo demonstrates a further substantial VC increase 
until the age of three years. This increase was especially evident 
for those vaccinations that are recommended to be administered 
by the end of the second year of life and for which individual 
catch-up later in childhood is recommended if timely vaccina-
tion had not taken place (i.e., 2nd MMR, 2nd VAR, MENC). 
The substantial increase in VC between 24 and 36 mo of age 
has been confirmed in our longitudinal approach; similar trends 
have been observed previously.15 It is important to note that vac-
cinations at around two years of age are usually given in one of 
several well-child check-ups in Germany. These examinations are 
distributed throughout the first months and years of life and take 
place at fixed age intervals.16 Check-up “U7” can be performed 
at covered costs between 20 to 27 mo of age. As a consequence, a 
number of vaccinations due until 24 mo of age are administered 
with a delay into the third year of life. This is also evident from 
previous surveys at regional level.7,10 However, even beyond the 
third year of life there is further substantial increase of VC as 
demonstrated by our longitudinal analysis of birth cohort 2004. 
Here, VC at higher age is comparable to figures seen in SEEs.17
ASHIP-specific analysis demonstrates that VC is not similar 
across ASHIP regions. This can be related to factors like vary-
ing time points in initial cost coverage through health insurance 
funds,8 state level particularities in vaccination recommenda-
tions,18 and historical background leading to generally higher 
VC in states of former East-Germany.17 Since regional variations 
are not reflected in country-level VC estimates, subnational VC 
data are crucial for assessing a country’s progress toward disease 
elimination. Health insurance claims data permit the analysis 
not only on ASHIP region or federal state level, respectively, but 
even on district level (data not shown), thus demonstrating an 
additional advantage over SEE.
More than half of all children in the investigated years of 
birth and ASHIP regions fulfilled the inclusion criteria for VC 
estimation. Children born in the investigated years of birth and 
ASHIPs represented more than two-thirds of all live births in 
Germany during 2004 and 2009. These figures let assume high 
representativeness of VC estimates for the studied years of birth 
and regions as well as for the population in Germany born dur-
ing this period. Moreover, validation with primary data looks 
promising. However, health insurance claims data provides only 
information on statutorily health insured individuals. It is not 
clear whether children of a different status differ in VC. Data on 
this remaining group that is mostly privately health insured is 
sparse. As recommended vaccinations are usually also covered by 
Table 1. characteristics of primary data sources kindergarten (Kee) and school (see) entrance examinations and corresponding data sets of the 
associations of statutory health Insurance Physicians (ashIPs) for validation of vaccination coverage (Vc) estimates
Period/place of 
data collection






















assumed month of examination august 
2009, resulting in birth periods:
PcV: Jul 06-aug 07
1st MMR, 1st VaR: Jan 04-sep 07
2nd MMR, 2nd VaR: Jan 04-May 08
MeNc: range: Jan 04-aug 07
other: Jan 04-aug 07
PcV: 24–37
1st MMR, 1st VaR: 
11–67




PcV: 1,314 (14 cohorts; mean 94)
1st MMR: 17,744 (57 cohorts; mean 311)
2nd MMR: 17,157 (53 cohorts; mean 324)
1st VaR 14,896 (57 cohorts; mean 261)
2nd VaR 14,387 (53 cohorts; mean 271)
MeNc: 3,789 (56 cohorts; mean 68)
Other: 15,843 (44 cohorts; mean 360)
MMR, VaR: counted as 1st and 2nd
MeNc: counted as single dose
Primary immunization with
PeR, PcV: 4 doses




IP 2004–09, ashIP 
schleswig-holstein
as in primary data source
as in primary data 
source
PcV: 12,791 (14 cohorts; mean 914)
1st MMR, 1st VaR: 52,035 (57 cohorts; 
mean 913)
2nd MMR, 2nd VaR: 47,181 (53 cohorts; 
mean 890)
MeNc: 50,691 (56 cohorts; mean 905)
Other: 38,542 (44 cohorts; mean 876)
as in primary data source
Vc for 3 and 4 doses from ashIP data 





















2009, federal state of 
saxony-anhalt
subgroup Jan-Jun 04 48–71
VaR: 6,555 (6,025 with vaccination card; 
91.9%)
Other: 7,566 (6,974 with vaccination card; 
92.2%)
MMR, VaR: counted as 1st and 2nd
MeNc: counted as single dose
Primary immunization with
PeR: 4 doses
PcV: 4 doses if 1st dose at 2–6 mo, otherwise 
3 doses
(if 1st dose at 7–11 mo) or 2 doses (if 1st 
dose at 12–23 mo)
Other: 4 doses (or 3 when administered 
without PeR component)
additionally: hIB if 1st dose at ≥12 mo
a
sh
IP 2004–09, ashIP 
saxony-anhalt
as in primary data source
61–66 (assumed 




as in primary data source
PeR, pertussis vaccine; hIB, Haemophilus influenzae type b vaccine; PcV, pneumococcal conjugate vaccine; MeNc, meningococcal c vaccine; MMR, measles, 
mumps, rubella vaccine; VaR, varicella vaccine.
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private health insurances, we assume to a large degree similar VC 
of children who are not contained in ASHIP data. In this regard, 
the authors of a bivariate and multivariate analysis in a popula-
tion-based cross-sectional study found no difference in propor-
tions of undervaccinated children from statutorily and privately 
health insured parents.19 Our sampling method for the analysis of 
ASHIP data excludes individuals with potential suboptimal VC 
such as children who receive their first vaccination very late or 
children of parents who completely refuse vaccinations. In addi-
tion, mobile groups like Roma/Sinti populations that are diffi-
cult to be reached by standard immunization programs20 are also 
possibly underrepresented in our approach resulting in a poten-
tially positive sampling bias and a slight VC overestimation.
In conclusion, analysis of health insurance claims data from 
ASHIPs allows for estimation of VC in Germany. It provides 
information on national and state level and contains residen-
tial data for resolution down to district level. Coverage of tra-
ditional and newly recommended vaccinations based on birth 
cohorts can be estimated in regard to whether childhood vac-
cinations have been administered in time and whether series of 
immunizations have been completed. ASHIP data analysis fills 
the information gap between early infancy and late assessment at 
school entry thereby facilitating more timely actions in modify-
ing and communicating national vaccination recommendations. 
Furthermore, data are at hand for children at 24 mo of age which 
is the international standard age for VC figures to be reported 
to the World Health Organization and the United Nations. 
Therefore, we conclude that ASHIP data analysis can serve to 
monitor compliance with childhood immunization recommen-
dations and suggest its implementation as a countrywide routine 
monitoring system in Germany.
Materials and Methods
Dataflow and database
ASHIPs regularly receive insurance refund claims from all 
ASHIP-associated physicians for ambulatory medical services 
delivered to statutory health insurees (~85% of the population 
in Germany). The administrative regions of most of the 17 
ASHIPs are organized per federal state. For our project, rel-
evant data are extracted from the ASHIPs’ databases and ano-
nymized by means of a hash algorithm. The algorithm includes 
an ASHIP-specific, non-changing password to generate a trun-
cated patient-specific identification (hash) code. Since 2004, 
an updated file is quarterly transferred to the Robert Koch 
Institute and imported into a database which has previously 
been described.21 In brief, the database contains vaccination 
data since 2004 and data on individuals’ physician consulta-
tions since 2008 (every first contact per quarter and medical 
specialization). Data include patient information (month/year 
of birth, sex, truncated zip code, and district of residence), phy-
sician information (medical specialization, district of practice), 
date of contact, and vaccination claim codes. Since 2008, these 
vaccination claim codes feature extensions that allow for the 
differentiation between doses not completing and completing a 
vaccination series.22
Table 2. availability of health insurance claims data for trend analyses of vaccination coverage (Vc) in cross-sections of birth cohorts from 2004 up to 
2009 at 24 and 36 mo by federal state and association of statutory health Insurance Physicians (ashIP)
VC at 24 mo VC at 36 mo
Federal state ASHIP 2004 2005 2006 2007 2008 2009 2004 2005 2006 2007 2008
Baden-Württemberg Baden-Württemberg + + +
Bavaria Bavaria + + + + +
Berlin Berlin +
Brandenburg Brandenburg + + + + + + + + + + +
Bremen Bremen
hamburg hamburg + + + + + + + + + + +
hesse hesse +
Lower saxony Lower saxony + + + + + + + + + + +
Mecklenburg-West Pomerania Mecklenburg-West Pomerania + + + + + + + + + + +
North Rhine-Westphalia North Rhine + + + + + + + + + + +
Westphalia-Lippe + + + + + + + + + + +
Rhineland-Palatinate Rhineland-Palatinate + + + + +
saarland saarland + + + + + + + + +
saxony saxony + + + + + + + + + + +
saxony-anhalt saxony-anhalt + + + + + + + + + + +
schleswig-holstein schleswig-holstein + + + + + + + + + + +
Thuringia Thuringia + + + + + + + + +
 Total: 9 11 12 13 14 15 9 11 11 13 14
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Data protection
The Federal Commissioner for Data Protection and Freedom 
of Information has approved the ASHIP vaccination monitoring 
project, in particular the data specification and the anonymiza-
tion procedure.
Sampling
As the patients’ identification code is generated from an 
ASHIP-specific algorithm, data can be assigned to a single patient 
only within his/her associated ASHIP but not across ASHIPs. 
Therefore, we sampled only those insurees who were seeking 
health services exclusively within their associated ASHIP by the 
following inclusion criteria: (1) Any vaccination soon after birth 
(0–4 mo of age) and a physician contact within a three month 
age-range at the end of the follow-up time are documented in 
the same ASHIP (e.g., at 24–26 mo for a VC assessment of up 
to 24 mo of age); in any case, we did not apply the three month 
age-range procedure before 2008, since data on physician consul-
tations were unavailable for that period; and (2) residency in the 
administrative region of this ASHIP at the time of these health 
service provisions.
Estimation of vaccination coverage and coverage trends
Data was aggregated using online analytical processing 
technology (OLAP) and prepared for analysis using ASHIP-
specific OLAP cubes connected via Excel 2010 (Microsoft). 
Histories regarding the vaccinations of interest were assembled 
for the sampled patients by counting vaccine doses on an 
individual level in a retrospective cohort approach. Samples were 
selected based on year of birth and ASHIP region or based on 
resembling cohorts (month/year of birth and age) of primary 
data sources for validation, respectively. We estimated VC for 
incomplete vaccination series (1st MMR and VAR) and for 
complete vaccination series defined as four doses of DIP, TET, 
PER, IPV, HIB, HEPB, and PCV, two doses of MMR and VAR, 
and a single dose of MENC, respectively. For external validation, 
these definitions varied (Table 1).
Analysis was performed in Stata 12 (StataCorp). VC was 
calculated as proportion of vaccinated individuals within the 
sample. Results at ASHIP level were weighted by the number of 
live births in the ASHIP region using population statistics23,24 
and summarized to nationwide VC. Intervals of 95% confidence 
were calculated.
Data from 10 to 15 ASHIPs were available for trend analyses 
in cross-sections of birth cohorts from 2004 to 2009 at 24 mo 
and from 2004 to 2008 at 36 mo (Table 2). For the longitudinal 
evaluation from birth to school entry, data from ASHIPs Saxony-
Anhalt and Schleswig-Holstein were exemplarily analyzed.
Validation of VC estimation
Comparison of VC with primary data sources
VC data from KEE 2009 in the federal state of Schleswig-
Holstein and SEE 2010 in the federal state of Saxony-Anhalt were 
used to externally validate VC estimates derived from ASHIP 
data analysis. Table 1 provides an overview on the sample char-
acteristics and definitions of the vaccination status.
In KEE, physicians who collect the relevant data can assess 
the children’s vaccination status by consultation of vaccination 
cards, the physician’s patient documentation system, and by 
interviewing the guardians. VC is calculated as number of chil-
dren having received a specified vaccine dose among all exam-
ined children of the same age of KEE. KEE data include age but 
not the date of examination. Therefore, in order to back-reference 
to month and year of birth, we assumed the month of routine 
school entry as examination date (August 2009), since many kin-
dergarten places become available in this month, and subtracted 
age at KEE. Month-of-birth cohorts were selected from ASHIP 
data that reached the respective age at KEE in August 2009. 
Subsequently, we compared VC of month-of-birth cohort pairs 
from KEE and claims data analysis at the age of KEE. Where 
necessary, VC from ASHIP data was weighted according to the 
different vaccination status definitions in KEE deriving from 
different types of data collection forms. Median VC differences 
and quartiles for box plot display were calculated. The analysis 
was limited to those cohorts who had reached or exceeded the 
earliest recommended age for the according vaccination in cases 
where KEE data collection forms required indicating the num-
ber of administered doses (MUM, MCV, RUB, VAR, MENC); 
for other vaccinations the analysis was limited to cohorts at the 
age of ≥24 mo. PCV vaccination for children was recommended 
since July 2006 and without catch-up vaccinations beyond the 
second year of life. Therefore, PCV analysis was limited to chil-
dren born July 2006 or afterwards.
VC data from SEE in Saxony-Anhalt was analyzed for 
children born in 2004. In SEE, only vaccinations documented 
on vaccination cards are considered, and the number of children 
who present vaccination cards is used as denominator (average 
case scenario). For our external validation of ASHIP-estimates 
we also calculated for each vaccination a worst case scenario for 
VC using the total number of children at SEE as denominator, 
assuming that children with missing vaccination documents lack 
the dose of vaccination investigated.
Re-capture of patients by screening for specific claim code 
extensions
The degree of VC underestimation due to intermittent loss 
to follow-up was assessed, i.e., an individual receiving intermit-
tent vaccinations by physicians of different ASHIPs. We there-
fore analyzed histories of vaccinations that were administered 
to a cohort born between July and December 2008 over a 24 
mo period in selected ASHIP regions. Code extensions for doses 
not completing vaccination series on the one hand and complet-
ing the series on the other were analyzed from five ASHIPs that 
applied them from July 2008 or earlier: Among the vaccinations 
of children who had a history of receiving two doses of MCV, 
MUM, RUB, or VAR or four doses of DIP, TET, PER, IPV, 
HIB, HEPB, or PCV, respectively, we calculated the proportion 
of doses falsely labeled as non-completing. Among the vaccina-
tions of children who had a history of receiving 1st MCV, MUM, 
RUB, or VAR or 3rd DIP, TET, PER, IPV, HIB, HEPB, or PCV, 
respectively, we also calculated the proportion of doses falsely 
labeled as completing. Assuming similar failure rates coding 
non-completing and completing doses in health insurance claims 
data, intermittent loss to follow-up and VC underestimation in 
the samples should be of concern if our calculated failure rate for 
coding non-completing doses were higher than the failure rate 
www.landesbioscience.com human Vaccines & Immunotherapeutics 9
for coding completing doses. This is because administered vac-
cinations missing in a patient’s history would mimic premature 
coding of a completing dose.
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